NCT05720052View on ClinicalTrials.gov

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
Relapsed or Refractory B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Marginal Zone Lymphoma (MZL)
Interventions
DRUG

MS-553

MS-553 oral tablet BID x 28-days

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Shenzhen MingSight Relin Pharmaceutical Co., Ltd

UNKNOWN

lead

MingSight Pharmaceuticals, Inc

INDUSTRY

NCT05720052 - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Biotech Hunter | Biotech Hunter